BioCentury | Mar 13, 2020
Management Tracks

Camerini steps down as Cosmo CSO; plus CytoDyn, G1 Therapeutics, Flexion and Clearside

...Gastrointestinal disorders company Cosmo Pharmaceuticals N.V. (SIX:COPN) said CSO Roberto Camerini has resigned. Luigi Moro, who...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...and Walther was general manager at the Aries Pharmaceuticals Inc. subsidiary of Cosmo Pharmaceuticals N.V. (SIX:COPN). Jonathan...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...Netherlands AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Atreca Inc., Redwood City, Calif. Cosmo Pharmaceuticals N.V. (SIX:COPN...
BioCentury | Jan 12, 2019
Finance

We all fall down

...prevent febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs Cosmo Pharmaceuticals N.V. (SIX:COPN...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...disease type C Phase II/III final data 1Q19 Paion AG (Xetra:PA8) / Cosmo Pharmaceuticals N.V. (SIX:COPN...
...Clovis Oncology Inc. (NASDAQ:CLVS) Rubraca rucaparib Ovarian cancer EU U.S. in 2016 Cosmo Pharmaceuticals N.V. (SIX:COPN...
BioCentury | Nov 30, 2018
Clinical News

FDA approves traveler's diarrhea drug from Cosmo

...FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive...
...Infectious Disease Product (QIDP) designation from FDA and was under Priority Review. Cosmo Pharmaceuticals N.V. (SIX:COPN...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs PDUFA date 11/3/18 Cosmo Pharmaceuticals N.V. (SIX:COPN...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...BioSciences Inc. (NASDAQ:CHRS) Biosimilar pegfilgrastim (CHS-1701) Neutropenia BsUFA; CHMP opinion 11/03/18; 2H18 Cosmo Pharmaceuticals N.V. (SIX:COPN...
BioCentury | May 25, 2018
Clinical News

FDA accepts NDA for Cosmo's antibiotic

...Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo...
...technology. The product has Qualified Infectious Disease Product (QIDP) designation from FDA. Cosmo Pharmaceuticals N.V. (SIX:COPN...
BioCentury | May 18, 2018
Company News

FDA accepts NDA for Cosmo's antibiotic

...Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo...
Items per page:
1 - 10 of 147